Grace Therapeutics, Inc. has received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for GTx-104, a novel injectable formulation of nimodipine aimed at treating aneurysmal subarachnoid hemorrhage (aSAH). The FDA’s CRL cites specific deficiencies in the Chemistry, Manufacturing, and Controls (CMC) and Non-Clinical sections, including issues related to leachables data, toxicology risk assessments, and manufacturing practices. Importantly, the FDA did not request additional clinical data, allowing Grace Therapeutics to focus on addressing the cited items for a resubmission.

The significance of this development lies in GTx-104’s potential to transform the treatment landscape for aSAH, a condition that has seen no meaningful innovation in over 40 years. The STRIVE-ON trial demonstrated that GTx-104 significantly reduced the incidence of clinically significant hypotension by 19% compared to oral nimodipine, along with improvements in relative dose intensity and functional outcomes at 90 days. These findings underscore the therapeutic advantages of GTx-104, particularly its ability to provide a more effective and safer delivery method for nimodipine, which is critical in managing the complications associated with aSAH.

The takeaway from this situation is the potential shift in the regulatory landscape for treatments targeting aSAH. Grace Therapeutics’ ability to resolve the FDA’s concerns could expedite the development timeline for GTx-104, paving the way for a new standard of care in aSAH management. This case highlights the importance of robust CMC and non-clinical data in drug development, particularly for conditions with high unmet medical needs, and may influence future research and regulatory strategies within the field of neurocritical care.

Source: globenewswire.com